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Background: Higher mortality has been found for people with serious mental illness (SMI, including schizophrenia,
schizoaffective disorders, and bipolar affective disorder) at all age groups. Our aim was to characterize vulnerable
groups for excess mortality among people with SMI, substance use disorders, depressive episode, and recurrent
depressive disorder.
Methods: A case register was developed at the South London and Maudsley National Health Services Foundation
Trust (NHS SLAM), accessing full electronic clinical records on over 150,000 mental health service users as a well-
defined cohort since 2006. The Case Register Interactive Search (CRIS) system enabled searching and retrieval of
anonymised information since 2008. Deaths were identified by regular national tracing returns after 2006.
Standardized mortality ratios (SMRs) were calculated for the period 2007 to 2009 using SLAM records for this
period and the expected number of deaths from age-specific mortality statistics for the England and Wales
population in 2008. Data were stratified by gender, ethnicity, and specific mental disorders.
Results: A total of 31,719 cases, aged 15 years old or more, active between 2007-2009 and with mental disorders
of interest prior to 2009 were detected in the SLAM case register. SMRs were 2.15 (95% CI: 1.95-2.36) for all SMI
with genders combined, 1.89 (1.64-2.17) for women and 2.47 (2.17-2.80) for men. In addition, highest mortality risk
was found for substance use disorders (SMR = 4.17; 95% CI: 3.75-4.64). Age- and gender-standardised mortality
ratios by ethnic group revealed huge fluctuations, and SMRs for all disorders diminished in strength with age. The
main limitation was the setting of secondary mental health care provider in SLAM.
Conclusions: Substantially higher mortality persists in people with serious mental illness, substance use disorders
and depressive disorders. Furthermore, mortality risk differs substantially with age, diagnosis, gender and ethnicity.
Further research into specific risk groups is required.
Background
The potential impact of mental disorders on mortality
has been increasingly recognised in recent years. People
with serious mental illnesses (SMI, including schizophre-
nia, schizoaffective disorder, bipolar disorder, and depres-
sive psychosis) live with health disparities, not only
resulting from social dysfunction, stigma, and direct
consequences of psychopathology, but also potentially
from the deleterious physical consequences of long-term
antipsychotic use and adverse lifestyle choices (e.g. smok-
ing, diet, illicit drug use, and physical inactivity), particu-
larly contributing to cardiovascular mortality [1-5].
Higher mortality has been found for people with serious
mental illness (SMI) in all age groups. In the US,
life expectancy for people with SMI from public mental
health agencies in eight states for 1997 through 2000 was
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general population [6]. In the UK, any psychiatric diagno-
sis was associated with a 65% higher than expected total
mortality in one case register study [7], and a three-fold
elevated mortality was found for coronary heart disease in
young adults with SMI in a primary care setting, as well as
an almost two-fold elevation for those aged 50-75 years,
and a more than two-fold increased stroke mortality in all
age groups [8]. Furthermore, a greater than 10-fold
increased risk of suicide mortality was found among the
same groups, itself associated with increased consultation
rates, antidepressant prescriptions, and residence in less
deprived areas [9].
Despite recent improvements in health care systems,
there has been little evidence for benefits on prolonging
life expectancy in people with SMI [5,10,11]. Instead, a
recent systematic review suggested a widening mortality
gap over recent decades with the pattern of change sug-
gesting a failure to benefit from population improve-
m e n t si nh e a l t hr a t h e rt h a na na c t u a li n c r e a s e dc a s e
fatality rate [11]. Given this persistence of excess mor-
tality, particularly in younger age groups, there is an
imperative need for further investigations in this area
[10,12,13]. Preliminary strategies for preventing prema-
ture deaths among people with SMI have been pro-
posed, including the management of suicide risk and
physical illness, minimizing polypharmacy, and improv-
ing accessibility to physical health care [1]. However,
there is limited evidence upon which to base these. Pre-
vious analyses of the UK General Practice Research
Database (GPRD) have only reported associations
between any SMI and mortality and did not differentiate
between disorders [8]. Further evidence is required to
clarify the characteristics of people with SMI who are at
highest risk of mortality.
We therefore investigated excess mortality for people
with individual disorders within the SMI grouping, as
well as for depressive and substance use disorder diag-
noses, drawing on data from the South London and
Maudsley NHS Foundation Trust Biomedical Research
Centre (SLAM BRC) Case Register, which covers com-
prehensive secondary mental healthcare provision to a
large geographically defined community.
Methods
Setting and study population
The SLAM BRC Case Register provides anonymised in-
depth information derived from electronic medical
records relating to secondary mental health care, which
includes all specialist care (i.e. apart from that provided
by general practitioners) for hospitalization, outpatient
care, a broad profile of community care models (both
acute care and rehabilitation), psychiatric liaison services
to general hospitals, and forensic mental health services.
The protocol for this case register has been described in
detail in an open-access publication [14]. SLAM pro-
vides comprehensive secondary mental health care to a
population of approximately 1.3 million residents of
four London boroughs (Lambeth, Southwark, Lewisham
and Croydon) as well as tertiary care national referral
units. Under the British National Health Service (NHS),
all secondary mental healthcare within these four bor-
oughs is provided at no cost to consumers by SLAM,
the only exception being people seeking exclusively pri-
vate healthcare [15]. Electronic clinical records have
been used comprehensively across all SLAM services
since 2006 and the Case Register Interactive Search
(CRIS) system was developed in 2008 to allow searching
and retrieval of anonymised information with over
150,000 cases currently represented on the system. CRIS
was approved as a dataset for secondary analysis by
Oxfordshire Research Ethics Committee C, reference
08/H0606/71.
This analysis focused on recorded mortality over a
three-year period from 2007 to 2009. Cases were
included if they had had contact with SLAM services
(a referral, discharge, or case note entry) from 1
st Jan,
2007 to 31
st Dec, 2009 and had received an SMI, sub-
stance use disorder, depressive episode, or recurrent
depressive disorders diagnosis before or during that
time. In the duration, routine mortality monitoring was
carried out on these patient records, hence patients
were “at risk” of death during this period of time. Date
of birth and gender were routinely recorded and verified
on the SLAM electronic patient electric records in
designated fields. Age was calculated at the 1
st of July,
2008 (i.e. the mid-point of the “at risk” period). All
those who were under the age of 15 at this date were
excluded from the analyses.
Mortality and covariates
NHS number is a unique identifier for UK NHS records,
all death certifications are linked to this identifier at a
national level, and primary and secondary health service
providers are required by law to keep records up to date
with respect to this. A list of deceased patients asso-
ciated with SLAM is downloaded on a monthly basis for
the “Service User Death Report” from “the Spine” pro-
vided by NHS Care Records Service for whom has been
marked as deceased by an update from another patient
demographic system. For non-active previous service
users, this was taken to be the date of death. Further
checking routinely occurs for active service users to cor-
roborate the death. The last monthly download was
31 March, 2010 and completed on 7 April, 2010. Diag-
noses recorded in the SLAM BRC Case Register were
based on the 10
th edition of the World Health Organiza-
tion International Classification of Diseases (ICD-10).
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SMI if they had received at least one of the following
diagnoses (identified by corresponding ICD-10 codes)
during their time in contact with SLAM services: schizo-
phrenia (F20), schizoaffective disorders (F25), and bipo-
lar affective disorder (F31). Substance use disorders (F10
to F19), depressive episode (F32) and recurrent depres-
sive disorder (F33) were also used for analyses. Separate
analyses were carried out for each disorder or grouping -
i . e .t h o s ew i t hm o r et h a no n ep r i m a r yd i a g n o s i sd u r i n g
the follow-up period could appear in more than one
‘case’ group. Ethnic group classifications applied in the
Case Register were: “White British”, “Other white back-
ground”, “East Asian”, “South Asian”, “African and other
black background”, “Caribbean”,a n d“Mixed, unknown,
and others”.
Statistical analysis
Standardized mortality ratios (SMRs) were calculated by
Stata for the three-year observation period, using the
number of deaths observed in SLAM records in these
three years as the numerator. The denominator was
the expected number of deaths in a year estimated by
age- and/or gender-specific mortality statistics for the
England and Wales population in 2008 multiplied by
three [16]. SMRs were calculated using age strata
(namely, 15-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45-49,
50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85-89,
and 90+) and also by gender and ethnicity strata for
specific mental disorders. Because the geographic catch-
ment area providing the majority of SLAM referrals was
restricted to southeast London, additional sensitivity
analyses were carried out using mortality statistics for
London alone in 2008, as published by the Office of
National Statistics [16], although, because of restrictions
in these source data, wider age strata had to be applied
for standardization (15-24, 25-34, 35-44, 45-54, 55-64,
65-74, 75-84, and 85+).
Results
A total of 38,066 cases were identified using CRIS with
a primary diagnosis, recorded before the end of March
2010, of substance use disorder, schizophrenia, schizoaf-
fective disorder, bipolar affective disorder, depressive
episode, or recurrent depressive disorder. Among these,
5,902 cases became inactive to SLAM services before
1 January, 2007 and remained inactive over the follow-
up period and were thus excluded from further analyses.
Those younger than 15 years old at the mid-point of
2008 or missing date of birth were also excluded (n =
445). Therefore, a total of 31,719 cases of interest with
1,370 deaths were identified. Of the sample, 1,680 (5.3%)
had two diagnoses of interest before the end of 2009,
121 (0.4%) had three diagnoses and six (0.02%) had four
diagnoses. The most common combinations of diag-
noses applied on different occasions in the same indivi-
dual were schizophrenia and schizoaffective disorders
(n = 421), followed by substance use disorders and
depressive episode or recurrent depressive disorder
(n = 352).
Figure 1 summarizes the data retrieval process and num-
ber of deaths in each group of interest. Age-standardised
mortality ratios (SMRs) of mental disorder diagnoses for
the total cohort and stratified by gender are displayed in
Table 1. Mortality was significantly elevated for all disor-
der groups - highest overall for substance use disorders,
followed by schizoaffective disorder, schizophrenia, bipolar
affective disorder and depressive episode. The ranking of
these disorder-specific SMRs was similar between men
and women, except that, in women, there were stronger
associations with schizoaffective and bipolar affective dis-
orders compared to schizophrenia. The SMR for any SMI
was stronger in men than women, principally because of
the marked gender difference for schizophrenia. SMRs for
depressive disorders were also higher for men compared
to women.
Table 2 displays age- and gender-standardised mortal-
ity ratios stratified by ethnic group. SMRs for SMI diag-
noses were comparable in size across all groups apart
from non-significant findings in the smallest East and
Subjects with any primary diagnosis of 
schizophrenia, schizoaffective disorders, 
bipolar affective disorder, substance use 
disorders, depressive episode, or 
recurrent depressive disorder (N = 38,066 
with 1,979 deaths) 
Active subjects with any of the 
above diagnoses during 2007 – 
2009 (N = 32,164) 
Male: 17,113; Female: 14,579 
(N = 31,719 with 1,370 deaths) 
Age < 15 years old on 1 Jul, 
2008 or missing date of birth (n 
= 445) 
Depressive episode, or 
recurrent depressive disorder 
(n = 11,697 with 620 deaths) 
Bipolar affective 
disorder (n = 2,700 
with 108 deaths) 
Schizoaffective 
disorders (n = 1,313 
with 44 deaths) 
Schizophrenia 
(n = 7,022 with 
322 deaths) 
Substance use 
disorders (n = 10,927 
with 348 deaths) 
Figure 1 Sample selection and diagnosis cohorts investigated.
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appeared more heterogeneous, although confidence
intervals were wide and overlapping.
As displayed in Table 3, SMRs for all disorders dimin-
ished in strength with increasing age. Even so, all disor-
ders remained significant predictors of mortality in the
oldest (65+ years) age stratum.
Secondary sensitivity analyses were carried out by
standardising with London mortality in 2008 (details not
s h o w n ) .I ns u m m a r y ,S M R sw e r ec o m p a r a b l ea n d ,i f
anything, slightly stronger than those displayed in
Tables 1, 2 and 3. For example, the re-calculated SMRs
f o ra n yS M Iw e r e2 . 2 1f o rt h et o t a ls a m p l e ,2 . 4 9f o r
men and 1.98 for women. The respective SMRs were
4.28, 3.70 and 4.76 for substance use disorders and 1.42,
1.72 and 1.29 for depressive disorders.
Discussion
In this analysis, people with mental disorder diagnoses
who had had contact with secondary mental healthcare
services, had substantially higher mortality than
expected in all diagnostic groups examined. The
calculated SMRs varied modestly by gender and sub-
stantially by age, and also fluctuated markedly across
different ethnic groups, which might be caused by small
size in specific populations.
People with SMI have substantially higher than
expected mortality in all age groups. The raised risk of
mortality in these cohorts is consistent with previous
studies, indicating that mortality rates among individuals
with SMI are higher than that of the general community
[6-8]. A previous longitudinal register-based study with
the maximum follow up of 18 years in the UK investi-
gated ‘any psychiatric diagnosis’ as an exposure and
found this to be associated with a 65% higher than
expected total mortality [7]. In our analysis, the SMRs
of those with SMI suggested a more than two-fold
higher mortality, although this may reflect a focus on
the more severe mental disorders represented within the
SMI label. Causal pathways between mental disorder
and mortality have yet to be fully elucidated and are
likely to be multiple. While suicide and accidents/vio-
lence are important considerations for clinical services,
research has tended to show mortality increases across
Table 1 Age-standardised mortality ratios (SMRs), stratified by gender, for mental disorder diagnoses in SLAM
#
Standardised mortality ratio for deaths in 2007-09
(95% CI, number of deaths)
Diagnosis Total Male^ Female^
SMI - any 2.15 (1.95-2.36, n = 446)* 2.47 (2.17-2.80, n = 243)* 1.89 (1.64-2.17, n = 203)*
Schizophrenia (F20) 2.25 (2.01-2.51, n = 322)* 2.78 (2.40-3.19, n = 196)* 1.74 (1.45-2.07, n = 126)*
Schizoaffective disorders (F25) 2.52 (1.83-3.39, n = 44)* 2.35 (1.35-3.86, n = 16)* 2.88 (1.91-4.16, n = 28)*
Bipolar affective disorder (F31) 1.95 (1.60-2.35, n = 108)* 1.76 (1.27-2.37, n = 43)* 2.21 (1.71-2.82, n = 65)*
Substance use disorders (F10 - F19) 4.17 (3.75-4.64, n = 348)* 3.60 (3.17-4.07, n = 254)* 4.67 (3.78-5.72, n = 94)*
Depressive episode and recurrent
depressive disorder (F32 - F33)
1.29 (1.19-1.40, n = 620)* 1.53 (1.36-1.72, n = 284)* 1.18 (1.06-1.31, n = 336)*
# Compared to the population of England and Wales in 2008.
* P-value <0.05.
^ Standardised by gender- and age-specific mortality rates, separately (27 missing values for gender).
Table 2 Age- and gender-standardised mortality ratios (SMRs), stratified by ethnicity, for mental disorder diagnoses in
SLAM
#
Standardised mortality ratio for deaths in 2007-09
(95% CI, number of deaths)
Ethnic group SMI
(F20, 25, & 31)
Substance use disorders
(F10 - F19)
Depressive episode and recurrent depressive disorder
(F32 - F33)
White British 1.97 (1.72-2.24, n = 224)* 3.94 (3.47-4.46, n = 250)* 1.30 (1.18-1.43, n = 455)*
Other white back ground 2.28 (1.74-2.92, n = 61)* 4.18 (3.08-5.54, n = 48)* 1.29 (0.99-1.64, n = 63)
East Asian 1.63 (0.65-3.35, n = 7) 0.87 (0.02-4.82, n = 1) 0.77 (0.25-1.81, n = 5)
South Asian 1.64 (0.79-3.02, n = 10) 6.55 (2.83-12.91, n = 8)* 1.93 (1.05-3.23, n = 14)*
African and other black
background
3.51 (2.61-4.62, n = 51)* 2.23 (1.02-4.23, n = 9)* 1.07 (0.46-2.11, n = 8)
Caribbean 2.06 (1.58-2.63, n = 64)* 2.73 (1.18-5.38, n = 8)* 1.52 (1.04-2.15, n = 32)*
Mixed, unknown, and others 3.21 (2.15-4.62, n = 29)* 3.76 (2.41-5.60, n = 24)* 1.39 (1.01-1.88, n = 43)*
# Compared to the population of England and Wales in 2008.
* P-value < 0.05.
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attack and stroke) [11]. These may be influenced by
direct effects of mental disorder symptoms (for example
on suicide and accidents). Pathways may also reflect
adverse lifestyle factors influenced by the presence of
mental disorders and themselves responsible for associa-
tions with mortality; these include worse nutrition, phy-
sical inactivity, alcohol use, smoking, and illicit drug use
[2-4]. Adverse effects from psychotropic (particularly
antipsychotic) medication have also received increasing
consideration in terms of their role in raised mortality
as an outcome [17]. Specifically, antipsychotic agents are
often prescribed long term and may increase the risks of
diabetes mellitus and cardiovascular diseases with events
including QT-interval prolongation, ventricular arrhyth-
mias, pulmonary embolus, atherosclerosis, and sudden
cardiac death [4,18-20]. The analyses presented here
were not intended to elucidate causal pathways, but
rather to constitute the first stage in a series of investi-
gations of these issues with future studies clarifying
further the role of socioeconomic status, education and
cognitive abilities which are all associated with higher
mortality and might confound the reported associations
[21,22].
Higher mortality in people with schizophrenia has
been recognised since the 1930 s [11]. Nonetheless, as
stated earlier, this mortality gap has remained stub-
bornly unchanged [10], and may even have increased
over time [5,11], despite developments in mental health
services and the introduction of better tolerated antipsy-
chotic agents. Previous studies suggest that around
two-thirds of the excess mortality among people with
schizophrenia may be attributable to natural causes, as
discussed above [23], with the remaining one third
being due to suicide and other unnatural causes [23-26].
Regarding bipolar disorder, a non-significant raised SMR
for all causes of death was reported in another study
performed in South London with a more limited sample
size (239 cases with 42 deaths over 19 years) [27].
Regarding SMRs for cases with depressive episode or
recurrent depressive disorder, a particularly high mortal-
ity risk was identified among the younger age stratum
(15-44 year olds, Table 3). However, the SMRs for
depression were relatively low [28]. This finding may be
due to the fact that people with depression known to
secondary care are not representative of those with the
disorder in the community and, in particular, that refer-
ral bias for secondary care favours those with relatively
good health or higher social class [29,30].
Our findings are, we believe, novel in the presentation
of SMRs stratified by age, gender, and ethnicity. Effect
modification, where demonstrated, may provide at least
some supportive evidence regarding causal pathways
since it indicates uneven distribution of risk; however,
such conclusions can only be drawn tentatively and
require confirmatory investigation. Gender differences in
the associations of interest might reflect different levels
of environmental support (for example, lower social sup-
port for men with schizophrenia might account for the
higher SMR in that group), or might reflect gender dif-
ferences in the severity of the condition in question or
in the level of comorbidity with other physical, mental
or personality disorder [31]. The substantial differences
in SMRs between ethnic groups again suggest that some
of the associations between SMI and mortality may be
socially mediated, although confidence intervals were
wide for many groups and negative findings should be
viewed with caution. The diminution of mortality risk
with age may reflect survival effects, with those surviv-
ing with serious mental disorder to age 65+ being rela-
tively healthier in other respects. Alternatively, people
with SMI in older age ranges may be more likely to
remain in contact with mental health services and
adhere to treatment, whether for mental or physical dis-
orders. However, the age diminution could also reflect
differences in the nature of the underlying disorders,
such as symptomatic differences between early- and
late-onset schizophrenia, or differences in substances
misused in younger and older adults. Further, it may
reflect the excess risk of SMI being additive rather than
Table 3 Age-standardised mortality ratios (SMRs), stratified by age group, for mental disorder diagnoses in SLAM
#
Standardised mortality ratio for deaths in 2007-09
(95% CI, number of deaths)
Diagnosis 15 - 44 years old 45 - 64 years old 65+ years old
SMI - any 4.47 (3.49-5.64, n = 71)* 3.10 (2.61-3.66, n = 140)* 1.60 (1.40-1.82, n = 235)*
Schizophrenia (F20) 4.73 (3.52-6.22, n = 51)* 3.44 (2.82-4.16, n = 106)* 1.63 (1.39-1.89, n = 165)*
Schizoaffective disorders (F25) 3.96 (1.81-7.52, n = 9)* 2.71 (1.48-4.55, n = 14)* 2.10 (1.30-3.21, n = 21)*
Bipolar affective disorder (F31) 4.09 (2.38-6.54, n = 17)* 2.58 (1.77-3.64, n = 32)* 1.51 (1.15-1.95, n = 59)*
Substance use disorders (F10 - F19) 6.81 (5.77-7.98, n = 153)* 4.40 (3.70-5.20, n = 139)* 1.91 (1.44-2.48, n = 56)*
Depressive episode and recurrent
depressive disorder (F32 - F33)
3.21 (2.40-4.20, n = 53)* 1.75 (1.35-2.22, n = 66)* 1.18 (1.08-1.28, n = 501)*
# Compared to the population of England and Wales in 2008.
* P-value < 0.05.
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Page 5 of 7multiplicative, so it is obscured by deaths from other
causes in older age groups [7,20].
This investigation has a number of strengths. We were
able to draw on a large numbers of case records from the
largest single provider of secondary mental healthcare in
Europe. The National Health Service presents additional
contextual advantages because of its near-total coverage
of all aspects of healthcare in the UK. This investigation
was able to draw on complete electronic clinical records
of more than 31,000 patients diagnosed with SMI,
depression or substance use disorders providing the sta-
tistical power to be able to differentiate between disor-
ders as well as explore subgroup-specific mortality risk.
However, potential limitations should also be consid-
ered. First of all, confounders other than age and gender
might still exist. Case registers derived from secondary
healthcare offer particular advantages for investigating
“high penetrance” disorders - i.e. those like schizophre-
nia and bipolar affective disorder where the chances of
secondary care contact are high. For lower penetrance
disorders, inferences need to be more cautious and both
depressive and substance use disorders fall into this
category - i.e. cases known to secondary care may reflect
more severe primary disorders, comorbidity, environ-
mental disadvantage or referral biases. Prevalence bias is
an additional issue which needs consideration, in that
the cases known to a service within a given time period
are likely to be dominated by those with long and relap-
sing clinical courses - they therefore cannot be taken to
generalise to incident cases. A further methodological
challenge was that service data were principally (but not
entirely) derived from a single catchment area whereas
expected deaths were derived from national data. How-
ever, a sensitivity analysis using London-specific data,
described above, did not reveal any meaningful differ-
ences. Finally, we have not included data on causes of
death and further research is required for this, as well as
for investigating specific risk factors for mortality within
particular disorders. Diagnostic categories overlapped
since a proportion of individuals suffer from more than
one mental disorder, but no attempt in this analysis was
made to consider comorbidity.
Conclusions
People with serious mental illness, substance use disor-
ders and depressive disorders continue to be at higher
risk of mortality compared to the general population.
Furthermore, mortality risk differs substantially with
age, diagnosis, gender and ethnicity. Further research
into specific risk groups is required.
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